---

OTOSCLEROSIS

A Comprehensive 50-Mark Answer

---

1. INTRODUCTION & DEFINITION

"Otosclerosis is a disease unique to the human temporal bone, in which the normally stable enchondral bone of the otic capsule undergoes pathological remodeling" — Cummings Otolaryngology, 7th Ed.

---

2. EPIDEMIOLOGY

---

3. ETIOLOGY & PATHOGENESIS

3.1 Genetic Basis

• Autosomal dominant with 25–40% penetrance
• Multiple loci identified: OTSC1 (chromosome 15q25-26), OTSC2 (7q34-36), OTSC3 (6p21-22), OTSC4 (16q21-23), OTSC5 (3q22-24), OTSC7 (6q13-16), OTSC8 (9p13.1-9q21.11)
• COL1A1 gene mutations associated in sporadic cases

3.2 Measles Virus Hypothesis

• Parainfluenza (measles) virus RNA detected in otosclerotic foci
• Measles vaccination has correlated with reduced incidence in some epidemiological studies
• Persistent viral infection may trigger abnormal bone remodeling (Cummings, 7th Ed.)

3.3 Hormonal Factors

• Estrogen accelerates disease — onset/worsening during pregnancy (40% worsen)
• Fluoride (sodium fluoride) may slow progression by blocking estrogen stimulation of bone resorption

3.4 Immunological

• Elevated IgG against type II collagen
• Increased TGF-β1, IL-1, TNF-α in otosclerotic foci
• Mast cell infiltration observed histologically

3.5 Other Factors

• Low fluoride intake (areas with non-fluoridated water have higher incidence)
• Vascular factors (hypervascular focus → abnormal osteoclast/osteoblast activity)

---

4. PATHOLOGY & HISTOPATHOLOGY

4.1 Site of Predilection

SITES OF OTOSCLEROTIC FOCI (in order of frequency):

1. FISSULA ANTE FENESTRAM (most common — 80–90%)
   → Anterior to oval window/stapes footplate
   → Causes stapes fixation → Conductive Hearing Loss

2. Posterior to oval window

3. Round window niche (10–30%) → Round window obliteration
   → Mixed / Sensorineural Hearing Loss

4. Internal Auditory Canal

5. Cochlear endosteum → Pure Sensorineural Hearing Loss (cochlear otosclerosis)

"The fissula ante fenestram is the most common site, present in almost all cases" — Hazarika, Textbook of ENT & Head-Neck Surgery

4.2 Histological Stages

• "Blue mantles of Manasse" — islands of newly formed bone with basophilic staining (pathognomonic)
• Hypervascular stroma (resembles hemangioma on CT)
• Irregular cement lines (mosaic pattern)
• Thickening and fixation of stapes footplate

---

5. CLASSIFICATION

5.1 By Site (Shambaugh's Classification)

5.2 By Stage (Siebenmann)

• Stage 1: Active, histological only, no hearing loss
• Stage 2: Partial fixation, mild CHL
• Stage 3: Complete fixation, severe CHL
• Stage 4: Cochlear involvement, SNHL/mixed

5.3 Footplate Classification (Surgical — Portmann)

---

6. CLINICAL FEATURES

6.1 Symptoms

A. Hearing Loss (Cardinal Symptom)

• Slowly progressive, bilateral, asymmetric conductive hearing loss
• Onset: insidious, 2nd–4th decade
• Initially affects low frequencies (Carhart's notch at 2 kHz)
• Paracusis Willisii (paracusis of Willis): Paradoxically better hearing in noisy environments (characteristic of otosclerosis — due to louder voice projection by others in noise while background reduces masking effect for the otosclerotic patient)
• Mixed hearing loss in cochlear involvement

B. Tinnitus

• Low-frequency tinnitus common
• May be the presenting symptom
• Worsens with disease progression

C. Vertigo / Dizziness

• Occurs in ~25% (cochlear/labyrinthine involvement)
• Mild, non-episodic in most cases

D. Speech

• Soft, mumbly voice (reduced bone conduction self-monitoring)
• Characteristic low voice — patient "hears" their own voice via bone conduction which is also reduced

E. Worsening During Pregnancy

• Classic history: hearing loss begins/accelerates during first pregnancy

6.2 Signs

Otoscopy

• Tympanic membrane — normal (key distinguishing feature)
• Flamingo pink blush / Schwartze Sign (positive in ~10% active disease):
  • Reddish/pink blush seen through tympanic membrane
  • Corresponds to hypervascular otospongiotic focus over promontory
  • Indicates active disease; sign of high surgical risk

Tuning Fork Tests (512 Hz)

"Gellé's test is specifically negative in otosclerosis due to fixation of the stapes footplate" — Zakir Hussain, Textbook of ENT

---

7. INVESTIGATIONS & DIAGNOSIS

7.1 Pure Tone Audiometry (PTA)

CHARACTERISTIC AUDIOMETRIC PATTERN IN OTOSCLEROSIS:

Frequency:   250   500   1000  2000  4000  8000 Hz
                                   ↓
Air Conduction: ─────────────────────────────── (flat/rising CHL)
                          ↑Carhart's Notch (2kHz, ~15dB dip in BC)
Bone Conduction: ────────────┘└────────────────

Air-Bone Gap: Present across all frequencies
Carhart's Notch: Mechanical artifact at 2000 Hz in BC curve
                 (not true SNHL — resolves after stapedectomy)

7.2 Impedance Audiometry (Tympanometry)

Type As (stiffness pattern) on tympanometry with absent acoustic reflex + normal TM on otoscopy = classical triad of otosclerosis (Cummings, 7th Ed.)

7.3 High-Resolution CT Scan (HRCT) of Temporal Bone

• "Halo sign" (Double ring sign): Hypodense halo around cochlea (particularly around basal turn and oval window region)
• Lucent focus anterior to oval window (fissula ante fenestram) — active otospongiosis
• Thickening/sclerosis of stapes footplate
• Obliteration of oval window niche in advanced disease
• Biscuit footplate (thickened footplate) visible on thin-cut axial slices

• Not routine; useful when:
  • Cochlear otosclerosis causing SNHL (halo around basal turn on T1 post-gadolinium)
  • Pre-cochlear implant assessment
  • Rule out retrocochlear pathology

7.4 Auditory Brainstem Response (ABR)

• Normal waveforms with conductive delay (increased absolute latencies)
• Rules out retrocochlear pathology in mixed/SNHL cases

7.5 Electrocochleography (ECoG)

• Summating potential changes in cochlear involvement

---

8. DIFFERENTIAL DIAGNOSIS

Van der Hoeve Syndrome (Osteogenesis Imperfecta + Otosclerosis)

• Triad: Blue sclera + Brittle bones + Otosclerosis
• Autosomal dominant; COL1A1/COL1A2 mutations
• Otosclerosis in 60% of osteogenesis imperfecta patients

---

9. MANAGEMENT

9.1 Overview — Management Algorithm

OTOSCLEROSIS MANAGEMENT FLOWCHART
═══════════════════════════════════════════════════════════════

DIAGNOSIS CONFIRMED
         │
         ▼
    ┌────────────────────────────────────────────────────┐
    │  Is patient fit/willing for surgery?               │
    └────────────────────────────────────────────────────┘
         │                              │
        YES                            NO
         │                              │
         ▼                              ▼
  ┌─────────────────┐           ┌───────────────────────┐
  │ Air-Bone Gap    │           │ MEDICAL MANAGEMENT +  │
  │ ≥ 30 dB?        │           │ HEARING AID           │
  └─────────────────┘           └───────────────────────┘
    YES    │    NO
           │    │
           │    ▼
           │  Hearing Aid only
           │  (or if only ear, SNHL,
           │   elderly, poor candidate)
           ▼
  ┌─────────────────────────────────┐
  │    SURGICAL MANAGEMENT          │
  │    Stapedectomy / Stapedotomy   │
  └─────────────────────────────────┘
         │
         ▼
  ┌──────────────────────────────────────────┐
  │ Footplate Assessment (Intraoperative)    │
  └──────────────────────────────────────────┘
         │
    ┌────┴───────────────┐
    │                    │
    ▼                    ▼
PARTIAL FIXATION    COMPLETE FIXATION
  ↓                      ↓
Stapedotomy          Stapedectomy or
(preferred)          Stapedotomy
                     (with/without laser)
         │
         ▼
   PROSTHESIS PLACEMENT
   (Teflon piston / Platinum-Teflon /
    Titanium / Gold prosthesis)
         │
         ▼
   POST-OP AUDIOGRAM (6–8 weeks)
   Success = ABG closure ≤ 10 dB

---

9.2 Medical Management

• Mechanism: Converts fluorapatite from hydroxyapatite → more stable bone; inhibits lysosomal enzymes; reduces osteoclastic resorption; theoretically halts progression to cochlear involvement
• Dose: 20–40 mg/day (Paget's disease dose: higher)
• Indications:
  • Active disease (Schwartze sign positive)
  • Progressive SNHL / cochlear otosclerosis
  • Post-operative residual SNHL
  • Patients unfit for surgery (slows progression)
• Contraindications: Pregnancy, renal failure, children (fluorosis risk)
• Duration: 2 years minimum; some advocate lifelong
• Combination: Often given with Calcium + Vitamin D

"Sodium fluoride therapy is indicated in active cochlear otosclerosis to prevent progression of sensorineural hearing loss" — Scott-Brown's Otorhinolaryngology, 8th Ed.

• Etidronate, alendronate studied; reduce bone turnover
• Role not fully established; under investigation (Recent Advances)

• Experimental; targeting vascular component of active otospongiosis

---

9.3 Surgical Management

INDICATIONS FOR SURGERY

CONTRAINDICATIONS TO SURGERY

---

9.4 Historical Evolution of Surgery

HISTORICAL MILESTONES IN OTOSCLEROSIS SURGERY:

1876 — Kessel: First stapes mobilization attempt
1890 — Boucheron & Miot: Stapes mobilization series
1938 — Lempert: Fenestration operation (one-stage)
       (Created new window in lateral semicircular canal)
1952 — Rosen: Re-popularized stapes mobilization
1956 — Shea: First successful STAPEDECTOMY (modern era)
       (Total footplate removal + vein graft + polyethylene strut)
1962 — Schuknecht: Fat-wire prosthesis
1978 — Fisch: Stapedotomy (small fenestra technique)
1989 — Perkins: CO₂ Laser stapedotomy
1990s — KTP, Argon, Er:YAG laser used
2000s — Robotic assistance, shape-memory alloys
2010s — Endoscopic stapedectomy

---

9.5 STAPEDECTOMY — Total/Partial Footplate Removal

STAPEDECTOMY — OPERATIVE STEPS:

1. PATIENT POSITION: Supine, head turned 30°, local/GA

2. INCISION:
   Endaural or retroauricular approach
   Elevation of tympanomeatal flap (posterior superior quadrant)

3. EXPOSURE OF MIDDLE EAR:
   Curette posterior bony canal wall if needed (chordal ridge)
   Identify: Pyramidal process, Stapedius tendon, Stapes,
             Long process of incus, Oval window

4. ASSESSMENT:
   - Confirm stapes fixation (palpation with probe)
   - Check cochlear reserve (speech — can patient hear?)
   - Assess footplate (biscuit, obliterative, floating)

5. MEASUREMENT:
   Measure distance from incus long process to footplate
   (usually 4.5–4.75 mm)

6. CHORDA TYMPANI NERVE: Preserved / gently displaced

7. INCUDO-STAPEDIAL JOINT SEPARATION:
   Divide with joint knife

8. STAPEDIUS TENDON SECTION:
   Cut with scissors/laser at pyramidal process

9. FRACTURE OF CRURA:
   Break/cut anterior and posterior crura (greenstick fracture)
   Remove suprastructure

10. FOOTPLATE MANAGEMENT:
    a. TOTAL STAPEDECTOMY: Remove entire footplate with picks
    b. PARTIAL STAPEDECTOMY: Remove posterior ½
    c. SMALL FENESTRA (STAPEDOTOMY): Create 0.6–0.8 mm hole
       with perforator/micro-drill/laser

11. OVAL WINDOW SEAL:
    Cover with: Vein graft / Fat / Perichondrium / Gelfoam

12. PROSTHESIS PLACEMENT:
    Hook loop over long process of incus
    Shaft into oval window (fenestra)
    Types: Robinson's bucket-handle, McGee, Causse, Fisch

13. TYMPANOMEATAL FLAP REPLACED
    Canal packed with Gelfoam
    External canal packed

---

9.6 STAPEDOTOMY (Small Fenestra Technique — Fisch, 1978)

• Smaller opening → less perilymph loss → better preserved cochlear function
• Lower rate of sensorineural hearing loss
• Reduced risk of floating/depressed footplate complications
• Better long-term results

1. Steps 1–9 as above (exposure, IS joint separation, crura removal)
2. Stapedotomy: Create 0.6–0.8 mm fenestra precisely centered in footplate
   • Manual: Perforator (Fisch type)
   • Drill: Micro-diamond bur
   • Laser: Most precise (CO₂, KTP, Argon, Er:YAG)
3. No oval window graft needed (small opening)
4. Prosthesis placed directly into fenestra

---

9.7 PROSTHESES — Types and Materials

---

9.8 LASER STAPEDOTOMY

• No mechanical trauma to footplate (no drill vibration)
• Precise, bloodless fenestration
• Ideal for obliterative otosclerosis
• Reduces risk of floating/depressed footplate
• Shorter operative time
• "One-shot" technique (CO₂ laser): Single pulse creates perfect fenestra

---

9.9 ENDOSCOPIC STAPEDECTOMY (Recent Advance)

• Introduced 2010s; growing popularity
• 0° and 30° rigid endoscopes (3 mm diameter)
• Advantages:
  • Better visualization (angled view — round window, oval window recess)
  • Single-handed technique
  • No need for speculum holder
  • Cosmetically superior (no retroauricular incision)
• Comparable outcomes to microscopic technique
• Limitation: Single-handed; learning curve; thermal injury risk from endoscope

---

10. INTRAOPERATIVE FINDINGS & COMPLICATIONS

10.1 Intraoperative Assessment

INTRAOPERATIVE FLOWCHART — FOOTPLATE FINDINGS:

           FOOTPLATE EXPOSED
                  │
     ┌────────────┼─────────────────┐
     ▼            ▼                 ▼
NORMAL         BISCUIT           OBLITERATIVE
FOOTPLATE      (Thickened)       FOOTPLATE
  ↓                ↓                  ↓
Confirm      Stapedotomy         Blue footplate
fixation     with perforator/    technique / Laser
             micro-drill          Drill through
                                  dense bone
                                  CAUTION: Floating
                                  footplate risk

10.2 Complications

Intraoperative

Early Postoperative

Late Postoperative

---

11. SURGICAL RESULTS & OUTCOMES

---

12. COCHLEAR IMPLANTATION IN OTOSCLEROSIS

• Bilateral severe-profound SNHL due to cochlear otosclerosis
• Failed or unsuitable for stapedectomy
• Poor cochlear reserve

• Obliteration of cochlear lumen by otosclerotic bone
• "Dead soft" or "dead bone" in cochlea — difficult insertion
• Fibrous/osseous obliteration of scala tympani
• Requires drilling through obliterated areas
• Reduced electrode insertion depth → poorer outcomes
• Higher electrical thresholds
• Special techniques: Tunnel drilling, Split electrode arrays, Double-array CI

"Cochlear otosclerosis presenting with severe SNHL is a recognized indication for cochlear implantation, but outcomes are somewhat inferior to other etiologies of SNHL" — Scott-Brown's, 8th Ed.

• HRCT: Grade cochlear obliteration
• MRI: Assess nerve integrity, fibrosis
• Promontory stimulation test

---

13. HEARING AID IN OTOSCLEROSIS

• Patient refuses surgery
• Only hearing ear
• Significant SNHL component
• Elderly/medically unfit
• Post-failed stapedectomy

• Conventional air conduction HA — most common
• BAHA (Bone Anchored Hearing Aid): For patients with absent air conduction route; excellent results in CHL
• CROS/BiCROS: Unilateral cases with poor contralateral ear

---

14. SURGICAL IMAGES

---

Figure 1: HRCT Temporal Bone — Otosclerosis Stages

---

Figure 2: Intraoperative Stages of Stapedectomy/Stapedotomy

---

15. RECENT ADVANCES IN OTOSCLEROSIS

15.1 Genetic and Molecular Advances

• Whole exome sequencing identifying novel OTSC loci
• COL1A1 polymorphisms (Sp1 binding site) confirmed as risk factor in multiple GWAS
• TGF-β1 as therapeutic target — anti-TGF-β therapy experimental
• RANKL/OPG pathway imbalance identified → bisphosphonate rationale

15.2 Imaging Advances

• Cone Beam CT (CBCT): Lower radiation dose; comparable to HRCT for fenestral otosclerosis
• MRI with gadolinium (3T): "Enhancement halo" on T1 post-Gd in active cochlear otosclerosis
• Quantitative CT densitometry: Measuring otic capsule density to grade activity
• Diffusion-weighted MRI: Research role in distinguishing active vs. inactive foci

15.3 Surgical Advances

• Robotic/Semi-robotic micromanipulators: Sub-millimeter precision in stapedotomy
• Shape-memory alloy (Nitinol) prostheses: Self-crimping; no manual crimping needed; reduced incus necrosis
• 3D-printed custom prostheses: Patient-specific geometry
• Endoscopic Ear Surgery (EES): Transcanal fully endoscopic stapedotomy — growing standard of care
• Laser advancements: CO₂ laser with microtargeting; pulsed mode reducing thermal spread
• Intraoperative monitoring: Cochlear microphonics, laser-Doppler vibrometry for real-time footplate assessment

15.4 Pharmaceutical Advances

• Bisphosphonates (alendronate/etidronate): Phase II trials in cochlear otosclerosis; comparable to NaF in slowing SNHL
• Anti-measles vaccination: Population-level data showing declining incidence in vaccinated cohorts
• Intratympanic steroids: Experimental for cochlear preservation in mixed otosclerosis

15.5 Cochlear Implantation Advances

• Hybrid/EAS (Electric-Acoustic Stimulation): For patients with residual low-frequency hearing + high-frequency SNHL from cochlear otosclerosis
• Scala vestibuli CI insertion in obliterated scala tympani
• Drill-out procedures with simultaneous CI

---

16. PROGNOSIS

---

17. SUMMARY FLOWCHART — COMPLETE MANAGEMENT

PATIENT WITH PROGRESSIVE BILATERAL CHL + NORMAL TM
                        │
                        ▼
           TUNING FORK TESTS
           Rinne: –ve  Weber: lateralizes to worse ear
           Gellé: –ve  ABC: Equal to examiner
                        │
                        ▼
           PURE TONE AUDIOMETRY
           CHL / Mixed HL + Carhart's Notch at 2 kHz
           ABG ≥ 30 dB
                        │
                        ▼
           IMPEDANCE AUDIOMETRY
           Type As tympanogram + Absent stapedial reflexes
                        │
                        ▼
           OTOSCOPY: Normal TM
           ± Schwartze sign (if active)
                        │
                        ▼
           HRCT TEMPORAL BONE
           Fenestral / Cochlear staging
           Assess footplate, obliteration
                        │
                        ▼
           ┌────────────────────────────────┐
           │      OTOSCLEROSIS CONFIRMED    │
           └────────────────────────────────┘
                        │
           ┌────────────┴─────────────┐
           │                          │
    FENESTRAL                   COCHLEAR / MIXED
    ABG ≥ 30 dB                  OTOSCLEROSIS
    Good cochlear reserve         ± SNHL
           │                          │
           ▼                          ▼
    SURGERY                    Sodium Fluoride
    Stapedotomy                + Ca + Vit D
    (preferred)                Consider CI if
    ± Laser                    severe SNHL
           │
           ▼
    POST-OP AUDIOGRAM
    Success: ABG ≤ 10 dB
    Speech discrimination ≥ 70%
           │
    ┌──────┴──────────┐
    │                 │
  SUCCESS           FAILURE
    │                 │
    ▼                 ▼
  Monitor         HA / Revision
  Annually        Stapedectomy /
                  Consider CI

---

18. TEXTBOOK REFERENCES

---

KEY POINTS FOR EXAM (50-Mark Summary)

1. Otosclerosis = focal otic capsule bony remodeling; unique to humans; predominantly whites, F>M, autosomal dominant (25–40% penetrance)
2. Most common site: fissula ante fenestram (anterior to oval window)
3. Histopathology: Blue mantles of Manasse; vascular stromal spaces (otospongiosis = active; otosclerosis = inactive)
4. Clinical hallmarks: Progressive CHL, normal TM, Paracusis Willisii, Rinne –ve, Gellé –ve, Schwartze sign (10% active)
5. Audiometry: CHL + Carhart's notch at 2 kHz + Type As tympanogram + absent stapedial reflex
6. HRCT: Fenestral hypodense focus + halo/double-ring sign (cochlear type)
7. Surgery of choice: Stapedotomy (small fenestra, 0.6–0.8 mm) with Teflon-platinum piston prosthesis
8. Laser stapedotomy: Gold standard in obliterative disease
9. Success rate: 90–95% (ABG ≤ 10 dB); dead ear risk: 0.3–1%
10. Medical: NaF for active/cochlear disease; bisphosphonates (emerging)
11. CI: For bilateral profound SNHL; challenges include ossified cochlea
12. Van der Hoeve syndrome: Otosclerosis + blue sclera + brittle bones
13. Recent advances: Endoscopic EES, nitinol prostheses, laser robotics, shape-memory alloys, anti-TGF-β therapy, GWAS genetics

---